Pharos I Bio Joins Lilly's AI Drug Discovery Platform
Proprietary AI Platform 'Chemiverse'
Connected to Lilly's AI and Big Data Infrastructure
Pharos I Bio, an artificial intelligence (AI) drug discovery company, announced on June 9 that it has signed an agreement to join the AI drug discovery platform 'Lilly Tunelab' operated by global pharmaceutical firm Eli Lilly.
Lilly Tunelab is an AI and machine learning (ML) collaboration program within 'Catalyze360,' Eli Lilly's open innovation platform. Based on federated learning technology, it is designed to allow pharmaceutical and biotech companies to participate in developing AI models without disclosing their data externally.
Pharos I Bio plans to leverage its accumulated experience in candidate discovery and clinical development, gained through its proprietary AI drug discovery platform Chemiverse, and connect this expertise to Eli Lilly’s AI and ML drug development environment. The company will review the physicochemical properties, druggability, and development potential of its key pipelines through this collaboration.
The company expects that this partnership will reduce the costs associated with securing large-scale data and AI infrastructure, while also verifying the global competitiveness of its Chemiverse-based candidates and development strategies. Moving forward, Pharos I Bio aims to pursue joint research and technology commercialization opportunities with global pharmaceutical companies, building upon its collaboration with Eli Lilly.
Hot Picks Today
"Koreans Spend 1 Million Won Each and Come Back"... 'They Said They Were Going for Value for Money,' but Open Their Wallets Wide in Japan- "I Drank It Every Day Instead of Water": The Surprising Drink That Could Cause Kidney 'Stones'
- [Exclusive] 15 Government Committees Have 'Zero' Appointed Female Members
- "I Have 9 Billion Won, but I Still Can't Quit"... The Unexpected Worry of a Major-Company Employee in His 40s Who Hit It Big with Investments
A representative from Pharos I Bio commented, “This marks the starting point for linking our expertise in candidate discovery and clinical development, accumulated through Chemiverse, with the AI and ML collaboration framework of global big pharma. We will continue to expand opportunities for global AI drug discovery collaborations.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
